Expression of the Inhibitor of DNA-binding (ID)-1 Protein As an Angiogenic Mediator in Tumour Advancement of Uterine Cervical Cancers

Overview

Journal Br J Cancer

Specialty Oncology

Date 2008 Nov 13

PMID 19002177

Citations 10

Authors

M K Maw

J Fujimoto

T Tamaya

Affiliations

Soon will be listed here.

Abstract

The ID protein, an inhibitor of basic helix-loop-helix (HLH) transcription factors, has been involved in multiple cellular processes. To investigate the association between tumour advancement and ID expressions of uterine cervical cancers, the levels of ID-1, ID-2 and ID-3 mRNAs were determined by real-time reverse transcription-polymerase chain reaction and the histoscore with the localisation of ID-1 was determined by immunohistochemistry and patient survival in 60 patients. ID-1 histoscores and mRNA levels both significantly (P<0.05) increased in uterine cervical cancers according to clinical stage regardless of histopathological type or lymph node metastasis. Furthermore, the 36-month survival rate of the 30 patients with high ID-1 was poor (60%), whereas that of the other 30 patients with low ID-1 was significantly higher (83%). ID-1 histoscores and mRNA levels significantly (P<0.0001) correlated with microvessel counts in uterine cervical cancers. Tumour cells show mostly diffuse to strong cytoplasmic expression of ID-1 and also very faint expression in endothelial cells. Moreover, ID-1 expression not only correlated with microvessel counts but also correlated significantly with histoscore. Therefore, ID-1 might work on tumour advancement through angiogenic activity and is considered to be a candidate for a prognostic indicator in uterine cervical cancers.

Citing Articles

Anti-tumor effects of an ID antagonist with no observed acquired resistance.

Wojnarowicz P, Escolano M, Huang Y, Desai B, Chin Y, Shah R NPJ Breast Cancer. 2021; 7(1):58.

PMID: 34031428 PMC: 8144414. DOI: 10.1038/s41523-021-00266-0.

PTBP3 Induced Inhibition of Differentiation of Gastric Cancer Cells Through Alternative Splicing of Id1.

Chen B, Chen W, Mu X, Yang L, Gu X, Zhao A Front Oncol. 2020; 10:1477.

PMID: 32974175 PMC: 7461954. DOI: 10.3389/fonc.2020.01477.

Inhibitor of DNA binding proteins: implications in human cancer progression and metastasis.

Ke J, Wu R, Chen Y, Abba M Am J Transl Res. 2019; 10(12):3887-3910.

PMID: 30662638 PMC: 6325517.

Uterine double-conditional inactivation of and in mice causes endometrial dysregulation, infertility, and uterine cancer.

Kriseman M, Monsivais D, Agno J, Masand R, Creighton C, Matzuk M Proc Natl Acad Sci U S A. 2019; 116(9):3873-3882.

PMID: 30651315 PMC: 6397514. DOI: 10.1073/pnas.1806862116.

Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy.

Antonangelo L, Tuma T, Fabro A, Acencio M, Terra R, Parra E Exp Biol Med (Maywood). 2016; 241(11):1159-68.

PMID: 26869608 PMC: 4950313. DOI: 10.1177/1535370216632623.

References

Wu M, Tzeng C, Wu L, Huang K, Chou C . Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis. Cancer J. 2004; 10(1):27-32. DOI: 10.1097/00130404-200401000-00007. View

Ohtani N, Zebedee Z, Huot T, Stinson J, Sugimoto M, Ohashi Y . Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature. 2001; 409(6823):1067-70. DOI: 10.1038/35059131. View

Norton J, Deed R, Craggs G, Sablitzky F . Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol. 1998; 8(2):58-65. View

Langlands K, Down G, Kealey T . Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell carcinoma. Cancer Res. 2000; 60(21):5929-33. View

Alani R, Hasskarl J, Grace M, Hernandez M, Israel M, Munger K . Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci U S A. 1999; 96(17):9637-41. PMC: 22262. DOI: 10.1073/pnas.96.17.9637. View

Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T . Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers. Br J Cancer. 1999; 79(7-8):1249-54. PMC: 2362259. DOI: 10.1038/sj.bjc.6690200. View

Singh J, Murata K, Itahana Y, Desprez P . Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. Oncogene. 2002; 21(12):1812-22. DOI: 10.1038/sj.onc.1205252. View

Giatromanolaki A, Sivridis E, Brekken R, Thorpe P, Anastasiadis P, Gatter K . The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer. 2001; 92(10):2569-77. DOI: 10.1002/1097-0142(20011115)92:10<2569::aid-cncr1609>3.0.co;2-3. View

Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L . Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001; 7(11):1194-201. DOI: 10.1038/nm1101-1194. View

10.

Riechmann V, Sablitzky F . Mutually exclusive expression of two dominant-negative helix-loop-helix (dnHLH) genes, Id4 and Id3, in the developing brain of the mouse suggests distinct regulatory roles of these dnHLH proteins during cellular proliferation and differentiation of.... Cell Growth Differ. 1995; 6(7):837-43. View

11.

Jang K, Han H, Paik S, Brown P, Kong G . Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Lett. 2006; 244(2):203-10. DOI: 10.1016/j.canlet.2005.12.016. View

12.

Schindl M, Schoppmann S, Strobel T, Heinzl H, Leisser C, Horvat R . Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res. 2003; 9(2):779-85. View

13.

Folkman J . Tumor angiogenesis. Adv Cancer Res. 1985; 43:175-203. DOI: 10.1016/s0065-230x(08)60946-x. View

14.

Ouyang X, Wang X, Lee D, Tsao S, Wong Y . Over expression of ID-1 in prostate cancer. J Urol. 2002; 167(6):2598-602. View

15.

Alani R, Young A, Shifflett C . Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci U S A. 2001; 98(14):7812-6. PMC: 35424. DOI: 10.1073/pnas.141235398. View

16.

Straume O, Akslen L . Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer. 2005; 93(8):933-8. PMC: 2361652. DOI: 10.1038/sj.bjc.6602792. View

17.

Polsky D, Young A, Busam K, Alani R . The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. Cancer Res. 2001; 61(16):6008-11. View

18.

Wernert N, Okuducu A, Pepper M . Ets 1 is expressed in capillary blood vessels but not in lymphatics. J Pathol. 2003; 200(5):561-7. DOI: 10.1002/path.1380. View

19.

Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A . Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature. 2000; 407(6804):592-8. DOI: 10.1038/35036504. View

20.

Le Jossic C, Ilyin G, Loyer P, Glaise D, Cariou S, Guguen-Guillouzo C . Expression of helix-loop-helix factor Id-1 is dependent on the hepatocyte proliferation and differentiation status in rat liver and in primary culture. Cancer Res. 1994; 54(23):6065-8. View